8-KLeadership Changes

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Feb 21, 2017)

Filed February 21, 2017For Securities:GILD

Summary

This 8-K filing by Gilead Sciences, Inc. (GILD) on February 21, 2017, primarily details compensation arrangements for its Executive Chairman, John C. Martin, Ph.D. The key takeaway for investors is the setting of Dr. Martin's 2017 base salary at $1,160,000. Additionally, he was granted stock options and performance share awards, each with a grant-date fair value of $2,000,000, effective February 16, 2017. The performance share awards are structured with a total shareholder return (TSR) tranche and a revenue tranche, with both components weighted at 50% of the award's fair value. The performance metrics and structure for these awards are substantially similar to those granted in 2016, indicating a continuation of the company's approach to executive incentive compensation. Investors should note that the specific number of shares and exercise price for the options will be determined by the company's stock price on the effective grant date.

Key Highlights

  • 1John C. Martin, Ph.D., Executive Chairman, has a 2017 base salary set at $1,160,000.
  • 2Dr. Martin received stock options with a grant-date fair value of $2,000,000.
  • 3Dr. Martin also received performance share awards with a grant-date fair value of $2,000,000.
  • 4The performance share awards are split 50/50 between a Total Shareholder Return (TSR) tranche and a revenue tranche.
  • 5The revenue tranche of the performance shares is divided into three separate annual subtranches.
  • 6Stock options will have an exercise price equal to the closing price of GILD common stock on February 16, 2017.
  • 7The compensation arrangements are designed to incentivize executive performance and align with shareholder interests.

Frequently Asked Questions

The primary purpose of this 8-K filing is to disclose the compensation arrangements, specifically the base salary and equity awards, for Gilead Sciences' Executive Chairman, John C. Martin, Ph.D., for the year 2017.

Dr. Martin's performance share awards are divided into two tranches: a Total Shareholder Return (TSR) tranche (50% of fair value) and a revenue tranche (50% of fair value). The revenue tranche is further broken down into three separate annual revenue subtranches.

The number of shares for the stock options will be based on their fair value on the effective grant date of February 16, 2017. The exercise price will be equal to the closing price of Gilead Sciences' common stock on that same date.

The filing states that the TSR and revenue tranches of the performance share awards will be structured in 'substantially the same manner' as the 2016 performance share awards, suggesting a continuation of Gilead's executive incentive compensation strategy.